AI in Oncology Market Size, Share, and Industry Analysis By Component (Devices/Hardware and Software & Services), By Cancer Type (Prostate Cancer, Breast Cancer, Lung Cancer, Brain Tumor, and Others), By Application (Diagnostics, Drug Discovery & Development, Radiation Oncology, and Others), By End User (Pharmaceutical and Biopharmaceutical Companies, Healthcare Providers & Others) and Regional Forecast, 2026-2034

The global AI in oncology market size was valued at USD 3.23 billion in 2025. The market is projected to grow from USD 4.19 billion in 2026 to USD 33.73 billion by 2034, exhibiting a CAGR of 29.77% during the forecast period.

The global AI in oncology market expands globally at high speeds due to rising adoption of artificial intelligence (AI) together with machine learning (ML) technologies in cancer treatment. These technologies present a paradigm shift in cancer diagnostics along with management and therapy which allows precision treatment strategies. The National Cancer Institute established that most oncologists believe artificial intelligence will transform cancer treatment as 95.6% of them identified its value for diagnosis and 89.2% for treatment along with 60.4% recognizing its application in managing side effects.

This market gains momentum due to increasing global cancer occurrence which requires advanced diagnostic resources together with treatment solutions as soon as possible. According to the International Agency for Research on Cancer (IARC), the global cancer cases reached 20 million in 2022 and scientists expect this number to increase to 35 million by 2050. The expanding cancer burden compels researchers and healthcare providers to utilize AI solutions as this helps both clinical results and healthcare expenses.

AI in Oncology Market Driver

AI Advancements Drive Growth in the Oncology Market, Enhancing Early Diagnosis and Treatment

Continuous technological advancements of AI together with machine learning and deep learning and computer vision systems constitute the main force behind the development of the AI in Oncology Market. Medical science is integrating these technologies at higher rates within oncology practice to boost both diagnostic precision and drug discovery process efficiency and enhance treatment design. AI algorithms process enormous medical datasets embracing images and genomic information as well as electronic health records so they can detect patterns which physicians might overlook.

Early and precise diagnosis which plays a crucial role in oncology treatment receives exceptional benefit from this capability. The research published in Frontiers in Oncology demonstrates that China and India rank among the leading countries conducting AI-based lung cancer research while China produces the most published studies. The world shows increasing interest in using artificial intelligence technology to solve cancer care problems.

AI in Oncology Market Restraint

High Implementation Costs and Data Privacy Concerns to Restrain AI Adoption in Oncology

Market growth in oncology AI technology faces various obstacles which block its promising advancement. AI market expansion encounters significant limitations through its high implementation and development expenses for new solutions. Current healthcare and research institutions must allocate substantial funds to develop technology systems and acquire patient data along with obtaining regulatory clearances before implementing AI solutions. Caring for patient data with sensitivity leads to security and privacy issues that must be overcome. AI implementation faces additional costs as healthcare organizations need to meet the requirements of major data protection laws including European GDPR and U.S. HIPAA. AI models face difficulties with accurate operation when trained on unstandardized cancer-related health data as they lack proper structure.

AI in Oncology Market Opportunity

AI-Driven Drug Discovery and Emerging Markets to Unlock Growth Opportunities in Oncology

The AI in oncology market contains various expansion possibilities mainly centered on pharmaceutical development alongside upcoming global market access opportunities. The drug discovery process stands to benefit from AI as such systems analyze vast data collections to detect suitable drug compounds faster than traditional methods. AI-based approaches shorten the development period and save expenses involved in creating new cancer therapies.

Predictive AI platforms help researchers find the most potent cancer cell treatment candidates through compound-cancer cell interaction assessments. The deployment of AI technologies within Asia Pacific and Latin America represents an important business opportunity for market players who seek to tap into emerging markets. Market players should exploit current opportunities in emerging regions that demonstrate fast healthcare development while people recognize AI's potential in oncology treatment.

Segmentation

Key Insights

The report covers the following key insights:

• Key Advancements: Technological Progress in AI and Machine Learning
• Growing Cancer Rates, By Key Countries
• Recent Partnerships and Product Launches
• Major Industry Trends

Analysis By Component

By component, the AI in oncology market is divided into devices/hardware and software & services. 

The software & services segment will control the market as healthcare settings continue to integrate AI-driven software solutions at an increasing rate. These solutions deliver state-of-the-art analytical functions and predictive modeling capabilities with decision support applications which are vital components for oncology professionals together with researchers.

Analysis By Cancer Type

By cancer type, the AI in Oncology market is divided into prostate cancer, breast cancer, lung cancer, brain tumor, and others. 

The market leadership of the lung cancer segment arises from prolonged research initiatives and widespread occurrence of lung cancer throughout the world. The leading research establishments working on AI-based lung cancer detection can be found in China and the U.S. due to the significant advancement potential that AI offers in fighting this deadly disease.

Analysis By Application

By application, the AI in Oncology market is divided into diagnostics, drug discovery & development, radiation oncology, and others. 

Due to its essential role in early cancer diagnosis diagnostic tools will lead the market as the primary segment. Medical institutions adopt AI systems to examine clinical data alongside imaging results alongside genomic information to detect cancer before it advances.

Analysis By End User

By end user, the AI in Oncology market is divided into pharmaceutical and biopharmaceutical companies, healthcare providers, and others. 

Healthcare Providers will take the lead role in the market as AI technologies continue to gain popularity in clinical settings. Healthcare institutions use AI technology to boost diagnostic precision and maximize therapeutic methods and raise the quality of medical treatment for patients.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on geography, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The AI in oncology market will be dominated by North America as this region maintains advanced healthcare facilities coupled with major technological investment into research and development and early AI technology implementation during clinical care. The U.S. stands as one of the leading global forces which supports AI-based cancer research and innovation.

The European market for AI oncology functions as a crucial segment since authorities provide backing for innovations while scientists deliver numerous research findings and healthcare professionals emphasize precise care strategies. AI adopts cancer care practices at an advanced level among United Kingdom, Germany, and France.

The Asia Pacific market is expanding quickly as healthcare investments rise as cancer patterns increase and nations dedicate more funds to AI technologies in healthcare. China together with India are strengthening their impact on AI-based cancer research which demonstrates the rising potential of their region.

Key Players Covered

The report includes the profiles of the following key players:

• Azra AI (U.S.)
• IBEX (Isreal)
• ConcertAI (U.S.)
• IBM (U.S.)
• PathAI, Inc. (U.S.) 
• Siemens Healthineers AG (Germany)
• General Electric Company (U.S.)
• Predictive Oncology (U.S.)
• NVIDIA Corporation (U.S.)
• Insilico Medicine (Hong Kong)

Key Industry Developments

• In October 2024, the cloud-based CareIntellect oncology system launched by GE HealthCare in October combines numerous patient datasets through generative AI technology to conduct clinical report summaries thereby supporting medical decisions in cancer diagnostics.
• In September 2024, F. Hoffmann-La Roche Ltd. shared plans to partner with Qritive to promote AI adoption among pathologists and improve cancer diagnostic accuracy as well as efficiency.
• In January 2024, as part of their collaboration, NVIDIA Corporation teams up with Deepcell to speed up generative AI applications in single-cell studies which will boost cancer biological research and aid in creating targeted treatments.